New Age Alpha Advisors LLC Buys 4,658 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• New Age Alpha Advisors LLC significantly increased its ownership of Intuitive Surgical, acquiring an additional 4,658 shares, raising its total stake by 221.4% to 6,762 shares worth approximately $3.35 million.
• Recent insider selling includes a notable transaction by EVP Myriam Curet, who sold 4,500 shares for over $2.2 million, prompting concerns about declining insider ownership.
• Intuitive Surgical reported strong Q2 earnings, beating estimates with an EPS of $2.19 on revenue of $2.44 billion, representing a year-over-year revenue increase of 21.4%.

New Age Alpha Advisors LLC increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 221.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,762 shares of the medical equipment provider's stock after purchasing an additional 4,658 shares during the period. New Age Alpha Advisors LLC's holdings in Intuitive Surgical were worth $3,349,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Parvin Asset Management LLC bought a new position in Intuitive Surgical during the fourth quarter valued at approximately $26,000. Chilton Capital Management LLC grew its position in Intuitive Surgical by 614.3% during the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 43 shares during the last quarter. Global Financial Private Client LLC grew its position in Intuitive Surgical by 253.3% during the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 38 shares during the last quarter. Elite Financial Inc. bought a new position in Intuitive Surgical during the first quarter valued at approximately $26,000. Finally, LFA Lugano Financial Advisors SA bought a new position in Intuitive Surgical during the first quarter valued at approximately $30,000. 83.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of the firm's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the transaction, the executive vice president owned 353 shares of the company's stock, valued at approximately $173,845.44. This trade represents a 92.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $563.11, for a total value of $121,631.76. Following the transaction, the senior vice president directly owned 907 shares of the company's stock, valued at $510,740.77. This represents a 19.23% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,903 shares of company stock valued at $7,932,778. 0.70% of the stock is currently owned by company insiders.

Intuitive Surgical Stock Down 1.3%

Shares of ISRG stock opened at $477.00 on Wednesday. The stock has a fifty day moving average of $521.43 and a 200 day moving average of $531.52. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $616.00. The firm has a market capitalization of $170.99 billion, a price-to-earnings ratio of 66.53, a PEG ratio of 5.07 and a beta of 1.59.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating the consensus estimate of $1.93 by $0.26. The business had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The company's revenue for the quarter was up 21.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.78 earnings per share. Equities research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

ISRG has been the topic of a number of recent research reports. Erste Group Bank reiterated a "hold" rating on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Wall Street Zen upgraded shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Deutsche Bank Aktiengesellschaft cut shares of Intuitive Surgical from a "hold" rating to a "sell" rating and reduced their price target for the company from $515.00 to $440.00 in a research report on Monday, June 9th. BTIG Research increased their price objective on Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Finally, Robert W. Baird dropped their price objective on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a research note on Wednesday, April 23rd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $595.95.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.